Table 1 Main clinical, metabolic data, medical treatment and atheromatous disease characteristics in the study population according to the presence of prediabetes
|  | Prediabetes (n = 2269) | Control group (n = 4419) | p |
|---|---|---|---|
Women, n (%) | 1290 (56.9) | 2151 (48.7) | < 0.001 |
Age (years) | 59 [54;64] | 57 [52;62] | < 0.001 |
HbA1c (mmol/mol) | 40 [39;42] | 36 [33;37] | < 0.001 |
HbA1c (%) | 5.8 [5.7;6.0] | 5.4 [5.2;5.5] | < 0.001 |
Dyslipidemia, n (%) | 1290 (56.9) | 2214 (50.1) | < 0.001 |
 Total cholesterol (mg/dL) | 206 [183;231] | 203 [179;229] | 0.002 |
 LDL-cholesterola (mg/dL) | 146 [133;164] | 145 [129;162] | 0.020 |
 HDL-cholesterola (mg/dL) | 53 [45;65] | 55 [46;67] | 0.009 |
 Triglyceridesa (mg/dL) | 148 [113;205] | 133 [100;183] | < 0.001 |
 Lipid-lowering agents, n (%) | 534 (23.5) | 712 (16.1) | < 0.001 |
 Statins, n (%) | 478 (21.0) | 656 (14,8) | < 0.001 |
 Fibrates, n (%) | 62 (2.7) | 54 (1.2) | < 0.001 |
 Ezetimibe, n (%) | 8 (0.3) | 17 (0.3) | 0.838 |
 Omega-3 fatty acids, n (%) | 6 (0.2) | 0 (0.0) | 0.001 |
Hypertension, n (%) | 1048 (46.2) | 1617 (36.6) | < 0.001 |
 Systolic BP (mm Hg) | 132 [120;142] | 129 [119;141] | < 0.001 |
 Diastolic BP (mm Hg) | 81 [75;88] | 81 [75;88] | 0.764 |
 Pulse pressure (mm Hg) | 49 [42;58] | 47 [40;56] | < 0.001 |
 Antihypertensives, n (%) | 911 (40.1) | 1305 (29.5) | < 0.001 |
 ACE inhibitors, n (%) | 430 (18.9) | 659 (14.9) | < 0.001 |
 ARA II, n (%) | 230 (10.1) | 334 (7.5) | < 0.001 |
 Diuretics, n (%) | 441 (19.4) | 586 (13.2) | < 0.001 |
 Beta-blockers, n (%) | 196 (8.6) | 216 (4.8) | < 0.001 |
 Calcium antagonists, n (%) | 147 (6.4) | 210 (4.7) | 0.003 |
 Other, n (%) | 12 (0.5) | 19 (0.4) | 0.573 |
Obesityb, n (%) | 817 (36.0) | 1176 (26.6) | < 0.001 |
 BMI (kg/m2) | 29.6 [26.7;33.1] | 28.0 [25.1;31.2] | < 0.001 |
Current or former smoker, n (%) | 1211 (53.4) | 2714 (61.4) | < 0.001 |
Antithrombotics, n (%) | 94 (4.1) | 115 (2.6) | 0.001 |
Number of CV risk factors | 2 [1;3] | 2 [1;2] | < 0.001 |
Characteristics of atheromatous disease | |||
 Presence of any plaque, n (%) | 1597 (70.4) | 2984 (67.5) | 0.017 |
 Carotid territory affected, n (%) | 1112 (49.0) | 1924 (43.5) | < 0.001 |
 Femoral territory affected, n (%) | 1227 (54.1) | 2321 (52.5) | 0.228 |
 Number of affected territories | 2 [1;3] | 1 [0;3] | 0.002 |
 Total plaque area, (cm2) | 0.96 [0.52;1.62] | 0.93 [0.56;1.55] | 0.760 |
 Stenotic lesions ≥ 50% | 21 (0.9) | 23 (0.5) | 0.057 |